7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
15th July 2019
Grayling is further strengthening its team with the addition of Andrew Kameka, who joins as an account director, in New York. Andrew brings to Grayling five years of experience in tech PR and a...Read More
17th June 2019
Environmental Defense Fund (EDF), one of the world’s largest environmental organizations, with more than two million members and a staff over 700 scientists, economist, policy experts and other...Read More
11th June 2019
To celebrate its 20th anniversary in Slovakia, Grayling has decided to share its experience contributing to the visibility of projects that are changing Slovakia for the better. In collaboration with...Read More